Connect your AI

Anika Therapeutics ANIK Accounts Receivable

Accounts Receivable at other companies

StrykerSYK

$3.57B-9.8%

VericelVCEL

$72.38M+36.8%

Zimmer Biomet HoldingsZBH

$1.73B+12.7%

Pacira BioSciences, Inc.PCRX

$125.64M+19.9%

BioventusBVS

$123.58M+2.2%

Xtant Medical HoldingsXTNT

$17.18M-26.8%

Other financials

Income statement

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total equity$133.9M-9.8%

Total assets$179.4M-5.9%

Cash flow

Operating cash flow-$4.8M-3,628%

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

P/S1.8×+0.1×

Profitability

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's accounts receivable?: Anika Therapeutics (ANIK) reported accounts receivable of $2.18M in Q1 2026.
How has Anika Therapeutics's accounts receivable changed year-over-year?: Anika Therapeutics's accounts receivable increased by 171.9% year-over-year, from -$3.03M to $2.18M.
What is the long-term trend for Anika Therapeutics's accounts receivable?: Over 3 years (2020 to 2023), Anika Therapeutics's accounts receivable has grown at a -64.2% compound annual growth rate (CAGR), from $24.1M to $1.1M.
What does accounts receivable mean?: Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.